Physician profile
David Fisk
NPI 1821049297
$2,748.89
in general payments reported to CMS, 2019-2025
17 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,108 · 2020: $511 · 2021: $538 · 2022: $91.94 · 2023: $116 · 2024: $262 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $500.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $700.15 | 2019-2023 | Apretude |
| Gilead Sciences, INC. | $494.84 | 2019-2022 | |
| Melinta Therapeutics, LLC | $372.74 | 2019-2024 | Rezzayo, Kimyrsa, Orbactiv |
| Merck Sharp & Dohme LLC | $260.07 | 2019-2021 | |
| Allergan, INC. | $157.22 | 2019-2020 | |
| Insmed, INC. | $152.46 | 2019-2020 | |
| La Jolla Pharmaceutical Company | $144.97 | 2021-2025 | Zevtera |
| Comsort, INC | $100.00 | 2019 | |
| Paratek Pharmaceuticals, INC. | $82.98 | 2020-2021 | |
| Tetraphase Pharmaceuticals, INC. | $65.58 | 2019 | |
| Pfizer INC. | $59.21 | 2019-2022 | |
| Abbvie INC. | $38.95 | 2021 | |
| Emd Serono, INC. | $33.42 | 2021 | |
| Ucb, INC. | $25.59 | 2020 | |
| Nabriva Therapeutics, Plc | $21.23 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $19.99 | 2020 | |
| Dynavax Technologies Corporation | $19.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Fisk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.